Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Almirall ( (ES:ALM) ).
Almirall’s shareholders approved the company’s individual and consolidated financial statements and management reports for 2025, along with its non-financial and sustainability information, formally endorsing the board’s management over the year. The meeting also ratified the allocation of €240.6 million in profit to legal and voluntary reserves and to offset prior-year losses, reinforcing the company’s balance sheet.
Shareholders authorized a dividend of €40.8 million to be paid from freely distributable reserves by early June 2026, signaling continued returns to investors alongside capital strengthening. They also approved amendments to the company’s Articles of Association related to the issuance of debentures and convertible instruments, potentially providing Almirall with greater flexibility in future financing and capital-structure management.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a pharmaceutical company focused on developing and marketing prescription medicines, particularly in dermatology and other specialty therapeutic areas. The company operates globally and targets both primary care and specialist markets, aiming to strengthen its position through innovation, regulatory compliance, and disciplined capital allocation.
Average Trading Volume: 149,849
Technical Sentiment Signal: Buy
Current Market Cap: €2.57B
For an in-depth examination of ALM stock, go to TipRanks’ Overview page.